Survival Benefit of Docetaxel Over Doxorubicin in Breast Cancer

[tousled1]

SAN ANTONIO, TX -- December 13, 2007 -- Breast cancer patients who received four cycles of a docetaxel-based adjuvant regimen achieved a survival advantage compared with women who received doxorubicin-based chemotherapy, according to results from 7 years of follow up.

Read full article:

http://www.docguide.com/news/content.nsf/news/852571020057CCF6852573B0006D1561